Latest Sales And Development News

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Aspen Group has upgraded its FY26 pre-tax earnings guidance by 6%, driven by strong rental income growth and development profits amid Australia's acute housing shortage. The company also announces a strategic acquisition of a new Sydney headquarters.

Scout Security reported a significant 62% reduction in operating cash outflows for Q3 FY2025, while advancing a potential acquisition and partnership opportunities following CES. The company’s cash position remains tight, prompting ongoing capital raising efforts.

Scout Security reports a 52% jump in quarterly cash receipts and a 31% reduction in operating outflows, while advancing plans to acquire New York’s Roo Inc.

First Graphene Limited reveals significant progress in commercialising its PureGRAPH graphene technology, highlighting expanding global partnerships and a robust sales pipeline valued over A$10 million.

Streamplay Studio Limited reported a remarkable 201% surge in operating revenue for FY25, driven by its strategic acquisition of Noodlecake Studios and expansion into new markets. Despite a wider operating loss, the company achieved positive cash flow and profitability in the final quarter, signaling a promising turnaround.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Saferoads Holdings Limited reported a net profit of $4.35 million for FY2025, driven largely by a $5.27 million gain from the sale of its Road Safety Rental business. Continuing operations showed a modest loss amid a 14% revenue decline.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Summerset Group Holdings Limited reported a robust first half in 2025, with underlying profit up 19% and record sales driving momentum across New Zealand and Australia.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

Rural Funds Group reported FY25 results aligned with forecasts, showcasing steady distributions and a diversified agricultural portfolio. The group maintains solid gearing and advances key development projects while forecasting stable AFFO and distributions for FY26.